Genmab A/S

GMAB

----

Current ValuationThe current P/E ratio is 29.50, within the reasonable range, cheaper than 48.2% of the time in the past 5 years, and the industry ranks 45/602, the industry Median -2.08.

29.5xP/E

Stock price$37.80Earnings per share$1.28

Historical Valuation

P/E ratioTypical rangeMedian

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.

019385776

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.

0x30x60x90x120x150x

P/E ratio
Name/Symbol
AMGNUSAmgen	24.90x	11.27%	$217.66B
VRTXUSVertex Pharma	28.90x	36.48%	$127.32B
REGNUSRegeneron Pharma	17.57x	7.98%	$76.05B
GMABUSGenmab A/S	29.50x	26.27%	$23.24B
UTHRUSUnited Therap	17.72x	6.05%	$23.23B
ASNDUSAscendis Pharmac	17.27x	470.27%	$14.87B
NBIXUSNeurocrine Biosciences	20.97x	50.69%	$14.79B
EXELUSExelixis	16.79x	16.33%	$14.45B
TGTXUSTG Therap	18.09x	64.86%	$7.99B
CDNAUSCaredex	29.73x	618.00%	$3.30B
PBYIUSPuma BioTech	18.35x	37.70%	$490.39M
KMDAUSKamada	21.03x	36.43%	$468.03M

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.